LEOPARD syndrome: Clinical diagnosis in the first year of life

LEOPARD syndrome (LS) is an autosomal dominant syndrome characterized by multiple lentigines and café‐au‐lait spots, electrocardiographic‐conduction abnormalities, ocular hypertelorism/obstructive cardiomyopathy, pulmonary stenosis, abnormalities of the genitalia in males, retardation of growth, and deafness. LS shares many features with Noonan syndrome (NS), in which lentigines and deafness are usually not present. Molecular studies have shown that LS and NS are allelic disorders, caused by different missense mutations in PTPN11, a gene encoding the protein tyrosine phosphatase SHP‐2 located at chromosome 12q22‐qter. The clinical diagnosis of LS is generally difficult in the first months of life because the distinctive lentigines are generally not present at birth and develop during childhood. From January 2002 to December 2004, we suspected LS clinically in 10 patients admitted to our genetic counseling services in the first 12 months of life. A PTPN11 gene mutation was detected in 8/10 (80%) patients. In one patient without a PTPN11 mutation a subsequent clinical diagnosis of neurofibromatosis type 1 (NF1) was made, following the evaluation of the mother, who had previously undiagnosed classic NF1. The age of LS patients with PTPN11 mutation ranged between 1 and 11 months (mean age ± SD 7.5 ± 3.96 months). Review of the clinical characteristics of patients with LS confirmed by molecular study during the first year of life demonstrates that the diagnosis of LS in the first months of age can be clinically suspected in patients presenting with three main features, that is, characteristic facial features (100%), hypertrophic cardiomyopathy (HCM) (87%), and cafe‐au‐lait spots (75%). Characteristic facial features can be mild or severe, and consist of hypertelorism, downslanting palpebral fissures, ptosis, and dysmorphic ears. The clinical suspicion of LS may be confirmed by molecular screening for PTPN11 mutations. An early diagnosis of the disease is useful for the prospective care of associated medical problems and for precise genetic counseling. © 2006 Wiley‐Liss, Inc.

[1]  C. Autore,et al.  Hyperthrophic cardiomyopathy and the PTPN11 gene , 2005, American journal of medical genetics. Part A.

[2]  J. Seidman,et al.  The PTPN11 gene is not implicated in nonsyndromic hypertrophic cardiomyopathy , 2005, American journal of medical genetics. Part A.

[3]  M. Patton,et al.  Genetic heterogeneity in LEOPARD syndrome: two families with no mutations in PTPN11 , 2005, Journal of Human Genetics.

[4]  T. Ogata,et al.  Two novel and one recurrent PTPN11 mutations in LEOPARD syndrome , 2004, American journal of medical genetics. Part A.

[5]  G Mortier,et al.  PTPN11 mutations in patients with LEOPARD syndrome: a French multicentric experience , 2004, Journal of Medical Genetics.

[6]  P. Fain,et al.  Genetic heterogeneity in the multiple lentigines/LEOPARD/Noonan syndromes , 2004, American journal of medical genetics. Part A.

[7]  M. Digilio,et al.  Clinical and molecular analysis of 30 patients with multiple lentigines LEOPARD syndrome , 2004, Journal of Medical Genetics.

[8]  D. Seripa,et al.  Correlation between PTPN11 gene mutations and congenital heart defects in Noonan and LEOPARD syndromes , 2003, Journal of medical genetics.

[9]  D. Baralle,et al.  Different mutations in the NF1 gene are associated with Neurofibromatosis–Noonan syndrome (NFNS) , 2003, American journal of medical genetics. Part A.

[10]  H. Ropers,et al.  Spectrum of mutations in PTPN11 and genotype–phenotype correlation in 96 patients with Noonan syndrome and five patients with cardio-facio-cutaneous syndrome , 2003, European Journal of Human Genetics.

[11]  R. Gibbs,et al.  PTPN11 Mutations in Noonan syndrome type I: detection of recurrent mutations in exons 3 and 13 , 2002, Human mutation.

[12]  J. Fryns,et al.  PTPN11 mutations in LEOPARD syndrome , 2002, Journal of medical genetics.

[13]  T. Ogata,et al.  PTPN11 (protein-tyrosine phosphatase, nonreceptor-type 11) mutations in seven Japanese patients with Noonan syndrome. , 2002, The Journal of clinical endocrinology and metabolism.

[14]  M. Digilio,et al.  Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene. , 2002, American journal of human genetics.

[15]  Bruce D Gelb,et al.  PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. , 2002, American journal of human genetics.

[16]  M. Porteous Management of genetic syndromes , 2002, Human Genetics.

[17]  Michael A. Patton,et al.  Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome , 2001, Nature Genetics.

[18]  J. Carey,et al.  Neurofibromatosis-Noonan syndrome. , 1998, American journal of medical genetics.

[19]  I. Temple,et al.  Multiple lentigines syndrome (LEOPARD syndrome or progressive cardiomyopathic lentiginosis). , 1997, Journal of medical genetics.

[20]  M. Burch,et al.  A clinical study of Noonan syndrome. , 1992, Archives of disease in childhood.

[21]  L. Blieden,et al.  Unifying link between Noonan's and Leopard syndromes? , 1983, Pediatric Cardiology.

[22]  R. Kalkhoff,et al.  Multiple lentigines syndrome. Case report and review of the literature. , 1976, The American journal of medicine.

[23]  J. Nordlund,et al.  The multiple lentigines syndrome. , 1973, Archives of dermatology.

[24]  R. Gorlin,et al.  Multiple Lentigenes Syndrome: Complex Comprising Multiple Lentigenes, Electrocardiographic Conduction Abnormalities, Ocular Hypertelorism, Pulmonary Stenosis, Abnormalities of Genitalia, Retardation of Growth, Sensorineural Deafness, and Autosomal Dominant Hereditary Pattern , 1969 .

[25]  G D'Hont,et al.  [The Noonan syndrome]. , 1982, Acta oto-rhino-laryngologica Belgica.